Clinical trial · Interventional
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
NCT00038428CI-TRIAL-00005271completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TLK286 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Histologic diagnosis of ovarian cancer * Recurrent or persistent disease following primary therapy * Measurable disease * Prior treatment with at least one but no more than three prior chemotherapy regimens * Resistant or refractory to platinum-based chemotherapy * At least 18 years of age * Good performance status (ECOG 0 to 1) * Adequate liver, renal and bone marrow function Exclusion criteria * Pregnant or currently breast feeding * Treatment with chemotherapy or immunotherapy within four weeks * Prior radiation to the whole pelvis
References
Publications (0)
Data not yet available
No reference posted for this study.